|RESEARCH & GENERAL NEWS |
| ||Physicians with St. George’s Vascular Institute in London, England have published the results of a “systematic review and meta-analysis of the mode of anesthesia and outcome after endovascular aneurysm repair (EVAR).” The review included published and unpublished literature and the primary outcome was 30-day mortality. The investigators isolated 10 studies including 13,459 patients total. The data did not indicate a different in 30-day mortality between those patients receiving local anesthesia (LA) and those receiving general anesthesia (GA). The report concluded by recommending further investigation of LA for EVAR “with better reporting of aneurysm morphology to clarify its potential benefits and identify the subgroups that will derive greatest benefit.” (Journal of Vascular Surgery) August, 2012|
Karthikesalingam A, Thrumurthy S, Young E, Hinchliffe R, Holt P, Thompson M. 2012. Locoregional Anesthesia for Endovascular Aneurysm Repair. Journal of Vascular Surgery. 56: 510-519.
| ||Researchers have published a report analyzing the technique and acute technical results “associated with the PowerWire Radiofrequency (RF) Guidewire used to recanalize central vein occlusions (CVOs) after the failure of conventional endovascular techniques.” The report consisted of a retrospective study, which included 42 patients who “underwent RF wire recanalization of 43 CVO’s, which were then implanted with stents.” All procedures had successful recanalization and 40 of the 42 patients had patent stents and were asymptomatic at 6 and 9 months after treatment. The results led the researchers to conclude that “the RF wire technique is a safe and efficient alternative in the recanalization of symptomatic and chronic CVO’s when conventional endovascular techniques have failed.” (Journal of Vascular and Interventional Radiology) August, 2012|
Guimaraes M, Schonholz C, Hannegan C, Anderson M, Shi J, Selby B. 2012. Radiofrequency Wire for the Recanalization of Central Vein Occlusions that Have Failed Conventional Endovascular Techniques. Journal of Vascular and Interventional Radiology. 23: 1016-1021.
| ||In comparing open repair and endovascular treatment of aneurysms of the braciocephalic trunk, researchers demonstrated by vascular imaging at a 8-year follow-up that "a stent graft was safely and successfully deployed to exclude" an aneurysm of the braciocephalic trunk. A group of physicians utilized endovascular treatment in order to compare it to the “significant morbidity and mortality rates” associated with open repair. The efficacy of the technique was demonstrated following the “good long-term outcome” of the endovascular procedure in treating “a large innominate artery true aneurysm due to Takayasu’s arteritis.” (Journal of Vascular Surgery) August, 2012|
Angiletta D, Marinazzo D, Guido G, Fullone M, Pulli R, Regina G. 2012. Eight-Year Follow-Up of Endovascular Repair of a Brachiocephalic Trunk Aneurysm due to Takayasu’s Arteritis. Journal of Vascular Surgery. 56: 504-507.
| ||Physicians with Baylor College of Medicine in Houston, Texas have published the results of a study designed to “test absorbable materials as a prelude to development of an absorbable vena cava filter for the prevention of pulmonary embolism (PE).” Three different types of polymer were considered: poliglecaprone (Monocryl; sizes4-0 and 1), polyglactin (Vicryl; sizes 4-0 and 1), and polydioxanone (PDSII; sizes 4-0, 2-0, 0, and 1). The tests were conducted in an “engineered closed circulation system that replicated human physiologic characteristics.” The materials were tested for efficacy via weekly tensile testing. The results indicated that “polydioxanone appears to be a strong candidate for novel absorbable vascular filters for PE prevention, with sufficient strength retention to catch emobli for at least 6 weeks and sequentially absorb via hydrolysis into CO2 and H2O within 22 weeks.” (Journal of Vascular and Interventional Radiology) August, 2012|
Eggers M, Reitman C. 2012. In Vitro Analysis of Polymer Candidates for the Development of Absorbable Vascular Filters. Journal of Vascular and Interventional Radiology. 23: 1023-1030.
|FDA & PERIPHERAL PRODUCT NEWS |
| ||Terumo has announced that it will be launching its PriorityOne AC Aspiration catheter in the United States. The PriorityOne is designed “to remove thrombi in the coronary and peripheral arteries and features a fully braided, stainless steel body and a kink-resistant stylet for easy navigation through the vasculature.” The device also features 6 Fr and 7 Fr guide catheter compatibility, as well as a hydrophilic coating. (MedGadget) August 23, 2012|
| ||Penumbra, Inc. has launched the 5Max reperfusion catheter for blood clot removal in patients experiencing acute ischemic stroke. The device “applies direct aspiration on the occlusion to optimize thrombus removal without the need for dual operators or the use of a large proximal balloon guide.” The 5Max features a tapered design for aspiration power that is equivalent to a 0.062-inch lumen of the same length. The device also “incorporates a polymer and nitinol coil reinforcement design at the distal tip to enable easy tracking through tortuous blood vessels.” The START trial is currently being conducted to evaluate the efficacy of the Penumbra system technology. (Endovascular Today) August 22, 2012|
| ||Toshiba America Medical Systems, Inc. has received FDA clearance for the company’s Aquilion RXL edition computed tomography (CT) system. The Aquilion RXL features a 16-detector row CT system with Toshiba’s Adaptive Iterative Dose Reduction 3D (AIDR 3D). According to Toshiba, the AIDR 3D “lowers the dose of radiation compared with conventional screening.” Additionally, the system includes Toshiba’s NEMA XR 25 dose-check software, “which improves user awareness of the radiation dose administered to patients.” (Endovascular Today) August 23, 2012|
|VIVA NEWS |
| ||The VIVA Conference will be returning to Wynn Las Vegas and will be held October 9 – 12, 2012. For information on VIVA and the 2012 Conference, please visit the following link: http://www.vivapvd.com|
|INDUSTRY/SPONSORED NEWS |
| ||S3V Vascular Technologies has announced plans to expand its medical device manufacturing facility at Vishakhapatnam (Vizag) by 2014. The Bangalore-based company “aims to develop next-generation products in intervention cardiology, neurology, peripheral and endovascular treatments.” The company is currently developing a product line, which will include catheters, disposables, and other devices used in various angiographic procedures in radiology and cardiology. S3V has already invested around $25M to establish a state-of-the-art integrated manufacturing facility in Bangalore, which will become fully operational by the end of 2012. (Pharmabiz.com) August 21, 2012|
|Are you interested in receiving more sponsored news? Please respond to email@example.com|
Help VIVA go green! Download these Free VIVA apps today.
|Stay up-to-date with the VIVA Dose app for the iPhone and iPod Touch, simply login in to iTunes, and install it.|
|Download VIVA's new iPad conference app to maximize your educational experience at THE national education course for vascular medicine and intervention! This app allows you to:|
| ||Create your own personalized schedule to organize and prioritize your time on site|
| ||View the most current daily agenda and faculty|
| ||Register directly from your iPad!|
|Download the app directly from your iPad or visit our website and select "Download the VIVA iPad App" icon from our homepage: www.vivapvd.com.|